Fail Early, Fail Fast – And Increase Likelihood-of-Approval

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how...

Top Blog Posts of 2016

As we ramp for a great 2017 we are looking back on what we did in 2016. As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views. FDA Introduces a New Test Concept: “Complementary...

Biomarkers and The Adoption Cycle: Where are we now?

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use...
October Webinar – Improving Your Biomarker Intelligence

October Webinar – Improving Your Biomarker Intelligence

We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related.  To see for yourself check out...

Chart of the Week: Phase 3 LOA Vs Precision Medicine Score

This week’s Chart of the Week attempts to communicate the correlation between a Company’s Precision Medicine Score and the Company’s Phase 3 Likelihood of Approval (LOA). This chart depicts how as a company increases their Precision Medicine Score, they...